JP2017511377A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511377A5
JP2017511377A5 JP2017501145A JP2017501145A JP2017511377A5 JP 2017511377 A5 JP2017511377 A5 JP 2017511377A5 JP 2017501145 A JP2017501145 A JP 2017501145A JP 2017501145 A JP2017501145 A JP 2017501145A JP 2017511377 A5 JP2017511377 A5 JP 2017511377A5
Authority
JP
Japan
Prior art keywords
formula
compound
disease
compounds
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501145A
Other languages
English (en)
Japanese (ja)
Other versions
JP6588962B2 (ja
JP2017511377A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022058 external-priority patent/WO2015143447A2/en
Publication of JP2017511377A publication Critical patent/JP2017511377A/ja
Publication of JP2017511377A5 publication Critical patent/JP2017511377A5/ja
Application granted granted Critical
Publication of JP6588962B2 publication Critical patent/JP6588962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501145A 2014-03-21 2015-03-23 神経疾患を治療するための方法 Active JP6588962B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968595P 2014-03-21 2014-03-21
US61/968,595 2014-03-21
PCT/US2015/022058 WO2015143447A2 (en) 2014-03-21 2015-03-23 Methods for treating neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019012873A Division JP2019065044A (ja) 2014-03-21 2019-01-29 神経疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2017511377A JP2017511377A (ja) 2017-04-20
JP2017511377A5 true JP2017511377A5 (enExample) 2018-03-29
JP6588962B2 JP6588962B2 (ja) 2019-10-09

Family

ID=54145492

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017501145A Active JP6588962B2 (ja) 2014-03-21 2015-03-23 神経疾患を治療するための方法
JP2019012873A Withdrawn JP2019065044A (ja) 2014-03-21 2019-01-29 神経疾患を治療するための方法
JP2020066670A Withdrawn JP2020109123A (ja) 2014-03-21 2020-04-02 神経疾患を治療するための方法
JP2022131705A Pending JP2022159555A (ja) 2014-03-21 2022-08-22 神経疾患を治療するための方法
JP2024205572A Pending JP2025022992A (ja) 2014-03-21 2024-11-26 神経疾患を治療するための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019012873A Withdrawn JP2019065044A (ja) 2014-03-21 2019-01-29 神経疾患を治療するための方法
JP2020066670A Withdrawn JP2020109123A (ja) 2014-03-21 2020-04-02 神経疾患を治療するための方法
JP2022131705A Pending JP2022159555A (ja) 2014-03-21 2022-08-22 神経疾患を治療するための方法
JP2024205572A Pending JP2025022992A (ja) 2014-03-21 2024-11-26 神経疾患を治療するための方法

Country Status (19)

Country Link
US (3) US10471029B2 (enExample)
EP (2) EP4289820A3 (enExample)
JP (5) JP6588962B2 (enExample)
KR (2) KR102645633B1 (enExample)
CN (1) CN106170563A (enExample)
AU (1) AU2015230972B2 (enExample)
CA (1) CA2941415A1 (enExample)
DK (1) DK3119911T3 (enExample)
ES (1) ES2960625T3 (enExample)
FI (1) FI3119911T3 (enExample)
HR (1) HRP20231172T1 (enExample)
HU (1) HUE063369T2 (enExample)
LT (1) LT3119911T (enExample)
PL (1) PL3119911T3 (enExample)
PT (1) PT3119911T (enExample)
RS (1) RS64744B1 (enExample)
SI (1) SI3119911T1 (enExample)
SM (1) SMT202300369T1 (enExample)
WO (1) WO2015143447A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289870A (zh) * 2015-09-10 2018-07-17 阿尔泽恩股份有限公司 治疗特定患者群体的神经变性病症的方法
JP6704050B2 (ja) * 2016-07-13 2020-06-03 株式会社マイトス 水素を有効成分として含む軽度認知障害又は認知症の予防又は治療用組成物
CN108623501B (zh) 2017-03-21 2022-04-19 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN110668980A (zh) * 2018-07-03 2020-01-10 浙江京新药业股份有限公司 一种2-取代的高牛磺酸衍生物
JP7466520B2 (ja) * 2018-08-01 2024-04-12 アルツェオン・インコーポレーテッド 神経変性障害を治療するためのスルホプロパン酸誘導体
IL280424B2 (en) * 2018-08-01 2025-01-01 Alzheon Inc Methods for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
WO2020257159A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN116059192B (zh) 2019-11-13 2024-10-29 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
IL321181A (en) 2022-12-02 2025-07-01 Alzheon Inc Methods for treating neurodegenerative disorders with termiprost

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE69333461T2 (de) * 1992-10-13 2005-03-24 Duke University VERFAHREN ZUM nachweis der Alzheimer Krankheit
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
SG145784A1 (en) 2003-08-11 2008-09-29 California Inst Of Techn Microfluidic large scale integration
SG10201502642TA (en) 2006-10-12 2015-05-28 Bhi Ltd Partnership Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
WO2012006329A2 (en) * 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
PT2994160T (pt) 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
KR20230056800A (ko) * 2014-02-08 2023-04-27 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
CN108289870A (zh) 2015-09-10 2018-07-17 阿尔泽恩股份有限公司 治疗特定患者群体的神经变性病症的方法
US20180250249A1 (en) 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population

Similar Documents

Publication Publication Date Title
JP2017511377A5 (enExample)
JP2020097577A5 (enExample)
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
JP2016521119A5 (enExample)
JP2016536286A5 (enExample)
JP2015024998A5 (enExample)
JP2019516739A5 (enExample)
JP2012504133A5 (enExample)
JP2017528503A5 (enExample)
JP2015501783A5 (enExample)
JP2017520613A5 (enExample)
JP2016518328A5 (enExample)
JP2013507415A5 (enExample)
JP2016539134A5 (enExample)
JP2018529698A5 (enExample)
JP2015508103A5 (enExample)
FI3119911T3 (fi) Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa
JP2016522254A5 (enExample)
JP2019529514A5 (enExample)
JP2016530265A5 (enExample)
JP2016510326A5 (enExample)
JP2010521516A5 (enExample)
JP2016539157A5 (enExample)
JP2018530608A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法